UFP Technologies stock
UFPTNASDAQUFP Technologies, Inc., HealthcareISIN US9026731029
76Score 76 out of 100, Strong
Price and trend
89 / 100
Price history
+29% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 22% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 53).
The price is 8.6% below its 52-week high. Largest decline in 20 years: 75% (May 2008 to March 2009).
Chart figures for advanced users
- SMA 50$292.58
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$251.41
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)53
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$185.45
- The lowest closing price of the last twelve months.
- Resistance$334.84
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- UFP Technologies, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $2.37B, is number 37 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $602.8M (up 19.5% year on year) and earnings of $68.31M (up 15.8%).
- For fiscal 2026, analysts expect on average revenue of $657.82M (up 9.1%) and adjusted earnings per share of $9.74 (down 0.6%).
Show more
- MEQIRI Score 76 out of 100 (Strong): rank 55 of 702 in Healthcare, median 53.
- The P/E is 31.2 (Medical (Devices) median 29.1, own median of recent years 24).
- Our model puts fair value at $224.01, with the price 37% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 37.7% a year since 2020.Growth 98
- Growing faster than its industryRevenue up 27.4% a year since 2020, Medical (Devices) median 13.8%.Growth 98
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 85
Weaknesses
- Volatile share priceVolatility 51% a year over the last 12 months.
Its standout strengths are growth and technical analysis, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 77 to 76.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $160.00 and expensive above $373.34 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $163.11 (cash-flow model) and $284.90 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $210.26, at 7.8% it would be $244.63.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 8.6% on the twelve months before. Revenue has grown solidly since 2006, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 28%, operating 15%, net 11%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 23 Feb 2027in 102 days
- Last reported
- 3 Nov 2026EPS reported $2.88 (expected $2.49)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $9.740.0%
- Revenue
- $657.82M0.0%
- Earnings per share
- $10.850.0%
- Revenue
- $698.95M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $12.92M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Kozin Marc DSale
25 Aug 2026, Board
- Shares
- 7,000
- Price
- $304.50
- Value
- $2.13M
- Hudson SymeriaSale
18 Aug 2026, Board
- Shares
- 298
- Price
- $319.11
- Value
- $95,095
- Hudson SymeriaSale
14 Aug 2026, Board
- Shares
- 1,926
- Price
- $324.58
- Value
- $625,141
Show 6 more
- Feldmann Cynthia LSale
13 Aug 2026, Board
- Shares
- 1,000
- Price
- $324.26
- Value
- $324,260
- Bailly R JeffreySale
10 Aug 2026, Executive Chairman
- Shares
- 13,011
- Price
- $316.13
- Value
- $4.11M
- Bailly R JeffreySale
7 Aug 2026, Executive Chairman
- Shares
- 5,013
- Price
- $317.87
- Value
- $1.59M
- Bailly R JeffreySale
6 Aug 2026, Executive Chairman
- Shares
- 10,682
- Price
- $318.63
- Value
- $3.4M
- Holt JasonSale
6 Aug 2026, Vice President
- Shares
- 1,100
- Price
- $317.00
- Value
- $348,700
- Feldmann Cynthia LSale
12 Jun 2026, Board
- Shares
- 1,200
- Price
- $239.29
- Value
- $287,149
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at UFP Technologies
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 76
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- TransMedics GroupTMDX $3.2B57
- iRhythm TechnologiesIRTC $3.1B30
- GN Store NordGN.CO $2.63B55
- NeogenNEOG $2.44B41
- Drägerwerk AG & Co. KGaADRW3.DE $2.31B66
- ElektaEKTA-B.ST $2.27B56
- Establishment Labs HoldingsESTA $2.05B41
- Butterfly NetworkBFLY $1.78B45
ETFs that hold UFP Technologies
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.14% | 0.30% | €185.82M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.14% | 0.30% | €2.31B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.08% | 0.30% | €2.22B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.08% | 0.30% | €4.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.05% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.03% | 0.10% | €395.74M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.02% | 0.35% | €8.27B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 19 Dec 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.